Regulation of ecto-apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3).
Amy E Baek, Yogendra Kanthi, Nadia R Sutton, Hui Liao, David J Pinsky
文献索引:FASEB J. 27(11) , 4419-28, (2013)
全文:HTML全文
摘要
The ectoenzyme CD39 suppresses thrombosis and inflammation by suppressing ATP and ADP to AMP. However, mechanisms of CD39 transcriptional and post-translational regulation are not well known. Here we show that CD39 levels are modulated by inhibition of phosphodiesterase 3 (PDE3). RAW macrophages and human umbilical vein endothelial cells (HUVECs) were treated with the PDE3 inhibitors cilostazol and milrinone, then analyzed using qRT-PCR, immunoprecipitation/Western blot, immunofluorescent staining, radio-thin-layer chromatography, a malachite green assay, and ELISA. HUVECs expressed elevated CD39 protein (2-fold [P<0.05] for cilostazol and 2.5-fold [P<0.01] for milrinone), while macrophage CD39 mRNA and protein were both elevated after PDE3 inhibition. HUVEC ATPase activity increased by 25% with cilostazol and milrinone treatment (P<0.05 and P<0.01, respectively), as did ADPase activity (47% and 61%, P<0.001). There was also a dose-dependent elevation of soluble CD39 after treatment with 8-Br-cAMP, with maximal elevation of 60% more CD39 present compared to controls (1 mM, P<0.001). Protein harvested after 8-Br-cAMP treatment showed that ubiquitination of CD39 was decreased by 43% compared to controls. A DMSO or PBS vehicle control was included for each experiment based on solubility of cilostazol, milrinone, and 8-Br-cAMP. These results indicate that PDE3 inhibition regulates endothelial CD39 at a post-translational level.
相关化合物
相关文献:
2014-02-01
[Arthritis Rheumatology 66(2) , 273-83, (2014)]
2013-11-01
[Plant Physiol. 147 , 1092-1109, (2008)]
1982-11-01
[Cancer Res. 42 , 4348-4352, (1982)]
2013-06-01
[Diabetes 62(6) , 2026-35, (2013)]
2009-01-16
[Immunity 30(1) , 56-66, (2009)]